Orlistat-Resveratrol Combination Improves Elastography Parameters Over and Above Weight Loss in Overweight/Obese Patients

Abstract

This 12-week, real-world, prospective, multicentre, randomized, controlled trial aimed to assess the safety and efficacy of combining Orlistat and Resveratrol compared to Orlistat alone in individuals with obesity or overweight, with or without metabolic syndrome. Both treatment groups demonstrated significant weight reduction from baseline, with the OrlistatResveratrol (O-R) combination group exhibiting higher weight loss than the Orlistat (O) alone group (-3.31 vs -2.92 Kg). Over 80% of participants in both groups achieved clinically significant weight loss (>5% of baseline weight). Assessment of liver health using Controlled Attenuation Parameter (CAP) scores indicated a significant reduction in hepatic steatosis in the O-R combination group compared to the O group (∆ -24.78 dB/m vs ∆ -11.78 dB/m), suggesting potential benefits of Resveratrol on liver health. Although the reduction in fibrosis scores was numerically higher in the O-R group, further research is needed to confirm these findings. This combination therapy shows promise in managing metabolic-dysfunction associated steatotic liver diseases (MASLD), warranting further investigation into its long-term efficacy and safety.